Peptide Therapy Billing & Coding: ICD-10, CPT, and HCPCS Guide for 2026

What Is Peptide Therapy?

Peptide therapy has emerged as one of the fastest-growing areas in regenerative and functional medicine. Peptides are short chains of amino acids — essentially fragments of proteins — that act as biological messengers, instructing cells to perform specific functions such as tissue repair, hormone regulation, immune modulation, and fat metabolism.

Compounds like Semaglutide, BPC-157, CJC-1295, Ipamorelin, TB-500, and PT-141 are now being prescribed across weight management, anti-aging, sports medicine, and sexual health clinics throughout the United States. As utilization grows, so does the complexity of billing and coding these services correctly.

Why Peptide Coding Is Challenging

Unlike conventional pharmaceutical drugs, many peptides lack a specific HCPCS J-code or NDC number because they are compounded — prepared by compounding pharmacies rather than manufactured as FDA-approved drugs. This creates a grey zone in medical billing where coders must rely on:

• Unlisted HCPCS codes (e.g., J3490 — Unclassified drug, or J3590 — Unclassified biologics)
• Compounding drug billing under the carrier's specific instructions
• ICD-10-CM diagnosis codes to demonstrate medical necessity
• Detailed documentation to justify coverage and avoid denial

FDA-approved peptides like Semaglutide (Ozempic, Wegovy) and Tirzepatide (Mounjaro, Zepbound) do have assigned NDC numbers and J-codes, making them easier to bill — but still requiring precise diagnosis coding to support medical necessity.

ICD-10-CM Codes for Peptide Therapy Indications

The diagnosis codes you assign depend entirely on the condition being treated. Here are the most common ICD-10-CM codes used alongside peptide therapy:

Weight Management / GLP-1 Agonists (Semaglutide, Tirzepatide)

• E66.01 — Morbid (severe) obesity due to excess calories
• E66.09 — Other obesity due to excess calories
• E11.65 — Type 2 diabetes mellitus with hyperglycemia
• Z68.35–Z68.45 — Body mass index range codes (use alongside E66.x)

Growth Hormone Peptides (CJC-1295, Ipamorelin, Sermorelin)

• E23.0 — Hypopituitarism (adult growth hormone deficiency)
• E34.8 — Other specified endocrine disorders
• R53.83 — Other fatigue (when fatigue is the chief complaint)
• M62.50 — Muscle wasting and atrophy, unspecified site

Tissue Repair Peptides (BPC-157, TB-500)

• M79.3 — Panniculitis, unspecified
• M25.50x — Pain in unspecified joint
• M54.5 — Low back pain (for spinal applications)

Sexual Health Peptides (PT-141 / Bremelanotide)

• N52.9 — Male erectile dysfunction, unspecified
• F52.0 — Hypoactive sexual desire disorder
• N94.10 — Unspecified dyspareunia (female)

CPT Codes for Peptide Administration

• 96372 — Therapeutic, prophylactic, or diagnostic injection (subcutaneous or intramuscular); most peptides are administered this way
• 99213 / 99214 — Office or other outpatient visit; for the evaluation and management component of the visit where peptide therapy is prescribed or reviewed
• 99401–99404 — Preventive medicine counseling; for wellness-focused peptide consultations

Important: If an E&M service is performed on the same day as the injection, append modifier -25 to the E&M code to indicate it was a significant, separately identifiable service.

HCPCS Codes for Peptide Drugs

Peptide	HCPCS Code	Notes
Semaglutide (Ozempic)	J0702	FDA-approved; use with E66.x or E11.x
Semaglutide (Wegovy)	J0703	FDA-approved for obesity; requires E66.x
Tirzepatide (Mounjaro/Zepbound)	J3380	Verify payer-specific NDC requirements
Sermorelin (compounded)	J3490	Unclassified drug; attach invoice and drug name
BPC-157 (compounded)	J3490	Unclassified; most payers do not cover
CJC-1295 / Ipamorelin	J3490	Unclassified; cash-pay or HSA in most cases
PT-141 (Bremelanotide)	J0900	FDA-approved; verify active coverage by payer

Documentation Requirements to Support Medical Necessity

Payer denials for peptide therapy are common — particularly for compounded peptides — because many commercial insurers and Medicare classify them as experimental or investigational. Strong documentation is your best defense:

• Diagnosis established — Confirmed ICD-10 diagnosis supported by lab results, imaging, or clinical assessment
• Failure of conventional therapy — Document that standard treatments were tried and failed or are contraindicated
• Treatment plan — Specific peptide, dose, frequency, route of administration, and expected duration
• Monitoring — Follow-up labs and clinical response documented at each visit
• Compounding pharmacy invoice — Required when billing J3490; include drug name, NDC if available, dose, and cost

Billing Tips for Compounded Peptides

1. Cash-pay disclosure: Most compounded peptides are not covered by insurance. Clearly inform patients upfront and use a cash-pay consent form.
2. Attach drug invoices: When submitting J3490 claims, attach the compounding pharmacy invoice as supporting documentation.
3. Avoid upcoding: Do not bill a specific J-code for a compounded peptide if no assigned code exists. J3490 and J3590 exist precisely for this purpose.
4. Verify state regulations: Some states restrict which peptides compounding pharmacies may produce. Ensure the peptide is legally compounded in your state before billing.
5. HSA/FSA eligibility: Patients paying out-of-pocket may use HSA or FSA funds for medically prescribed peptide therapy.

Key Takeaways

• Use J-codes with NDC for FDA-approved peptides (Semaglutide, Tirzepatide, Bremelanotide)
• Use J3490 with an attached invoice for compounded peptides
• Always pair with a specific ICD-10-CM diagnosis code that documents medical necessity
• Bill the administration with CPT 96372 and the E&M with modifier -25 when both are performed the same day
• When in doubt, bill cash-pay and document thoroughly for potential future reimbursement

As peptide therapy continues to move into mainstream medicine, payer policies will evolve. Stay current with your payer's medical policies and check for updated J-code assignments each quarter through the CMS HCPCS update bulletins.